Conditions: Breast Neoplasms Breast Cancer
Keywords: Cancer
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 54
Healthy volunteers: no

Brief summary:
The purpose of this study is to evaluate the anti-cancer activity and safety of BAY43-9006 (Sorafenib) in patients, who suffer from an advanced breast tumour, which has spread to other organs of body despite treatment that the patient has received so far.

Detailed description:

Arms:
arm 1: Sorafenib 400 mg administered twice daily (b.i.d.)

Interventions: intervention 1: Sorafenib (Nexavar, BAY43-9006)
Intervention descriptions: intervention 1: Sorafenib 400 mg administered twice daily (b.i.d.)

Protocol document: